Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R9Z vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) Buyback Yield % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a Buyback Yield % of -22.51 as of Aug. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #510 out of 725 companies in the Biotechnology industry, placing it in the top 70.3%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Buyback Yield % too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Buyback Yield % is -22.51. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #510 out of 725 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #510 out of 725 companies for Buyback Yield %. This places ImmuneOnco Biopharmaceuticals (Shanghai) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Buyback Yield % is -22.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current Buyback Yield % of -22.51. The current Buyback Yield % is -22.51. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current Buyback Yield % is -22.51 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
7GF Score
Get the complete analysis for FRA:R9Z
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R9Z has been successfully added to your 
